PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143345
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143345
Spatial OMICS market size was valued at US$ 320.8 Million in 2025, expanding at a CAGR of 9.9% from 2026 to 2033.
Spatial OMICS is a series of advanced techniques that can be used for the measurement and formation of spatial maps to quantify the presence of biological molecules such as RNA, protein, and metabolite in tissue sections, taking into account tissue architecture. In general, the Spatial OMICS technology consists of the combination of high-throughput sequencing and mass spectrometry technologies with imaging/microdissection technologies. Due to this technology, it becomes possible to correlate molecular data with the location in cells and tissues. This opens up the possibility of using ORIMS technology from the point of view of tissue architecture and thus creates an entirely new paradigm for understanding tumor heterogeneity and disease progression at a cellular, tissue, and positional level.
Spatial Omics Market- Market Dynamics
Advancements Of Precision Medicine To Propel Market Growth
The growing advancements in precision medicine are driving the adoption of spatial omics technologies. This is because detecting the locations of the genes, proteins, and other molecules increases the understanding of how diseases work, and it allows the identification of biomarkers that predict the patients' response to the therapy and finding out their uniqueness. For example, according to the NIH Gov, in February 2026, advances in genomics play an important role in precision medicine by offering treatments that match patients' genomes, environments, and lifestyles.
In particular, by July 9, 2025, the total number of phenotypes is 7634; the molecular mechanism for 799 phenotypes is known. This helps in screening and prevention of such diseases and helps in better treatment of such diseases. It is also found that 10% of respondents reject the concept of genetic testing, as they feel that it may be used against them, whereas 30% of the people refuse to go for genetic testing due to this reason. Therefore, these facts explain why the adoption of spatial omics technologies will be increasing in precision medicine and other healthcare fields.
The Global Spatial Omics market is segmented on the basis of Technology, Workflow, Product, Sample, Application, End User, and Region.
Based on technology, the spatial transcriptomics segment holds a prominent share in the spatial biology market. This technology is being commonly used to understand the gene expression while keeping the spatial identity of the cells or tissues, thus being used in several applications like research on diseases, drug discovery, research of cancerous tumors, and tissue biology. In March 2026, 10x Genomics formed a strategic alliance with Bioptimus in order to develop the STELA spatial biology atlas that will make use of the Xenium spatial transcriptomics platform as the core technology in creating spatial datasets. These advancements are expected to enhance spatial transcriptomics adoption across research and clinical applications.
Spatial Omics Market- Geographical Insights
The North American region represents one of the important regions for the spatial OMICS market, as the region has a considerable number of investments made for its research and development activities. In March 2026, according to United for Medical Research (Org.), NIH provided a total amount of $36,580 million (USD) as research grants for organizations in 50 US states and the District of Columbia in the financial year 2025. The NIH research funding created 390,863 jobs and $94,150 million (USD) in economic activity in 2025. Each dollar invested in NIH research created 2.57 times the economic activity, i.e., the return on investment is 250%. The investment made by NIH in the past decade nationally has created $822,000 million (USD) of economic activity and 3.7 million jobs in the last decade nationally. These are expected to bolster research capabilities and growth potential of the Spatial Omics market in the region.
South Korea Spatial Omics Market - Country Insights
South Korea is currently growing rapidly because of the rise in the number of research centers focusing on innovation as well as the contribution of the government towards the development of biotechnology. For instance, as stated by Korea On Point Org, in July 2025, South Korea's Bio Economy Initiative will place the nation among the top five bio-economies in the world by 2030. This will be made possible due to increased bio-manufacturing ecosystems, clinical trials of vaccine subsidies, and personalized medicines. In addition, the role of the government will continue in the development of biotechnology through various initiatives aimed at developing a bioeconomy in the country and helping grow the market in the forecasted period.
The Spatial Omics market comprises a number of existing as well as upcoming competitors, who are competing against each other in the development of new sequencing, imaging, multiplexing, and single-cell technologies so as to establish themselves in a better position in the market. Companies such as 10x Genomics, Illumina, NanoString, Akoya Biosciences, and Resolve Biosciences are just some of the prominent players that have gained significant recognition in the market through the use of integrated spatial analysis platforms and differentiating imaging technology. In June 2026, Illumina launched StrataMap Spatial Solution, which is an end-to-end sequencing-based spatial whole-transcriptome research solution that offers single-cell resolution, a larger capture area, and unbiased whole-transcriptome profiling in spatial biology research and discovery. Such developments can be beneficial for companies to conduct spatial biology research with greater resolution and whole-transcriptome profiling.
In April 2025, Akoya Biosciences disclosed its collaboration with Enable Medicine to create the largest single-cell spatial proteomics atlas commercially available using over 100 million cells in 8,500+ samples and 15+ cancers in order to characterise the tumour microenvironment using Akoya's PhenoCycler-Fusion technology.